TDC
GBT

Thompson Davis & Co’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Thompson Davis & Co’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		$5K Sell
125
-400
-76% -$17.7K 0.01% 584
2018
Q2 		$24K Buy
525
+150
+40% +$6.83K 0.06% 290
2018
Q1 		$18K Hold
375
– – 0.05% 318
2017
Q4 		$15K Buy
+375
New +$14K 0.04% 361

Other funds holding GBT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Thompson Davis & Co's GBT Position: Q3 2018 in Review

Thompson Davis & Co reduced its Global Blood Therapeutics, Inc. (GBT) stake by 76% in Q3 2018, selling an estimated $17.7K and leaving 125 shares worth $5K. The position accounts for 0.01% of the portfolio, ranked #584.

Thompson Davis & Co first reported a position in GBT in Q4 2017 and has held it in 4 quarters since. The position peaked at $24K in Q2 2018. 184 funds tracked by Wall St. Rank hold GBT as of Q3 2018.

  • Thompson Davis & Co held 125 shares of Global Blood Therapeutics, Inc. worth $5K as of Q3 2018.
  • Thompson Davis & Co sold 400 Global Blood Therapeutics, Inc. shares in Q3 2018, an estimated $17.7K.
  • Global Blood Therapeutics, Inc. made up 0.01% of Thompson Davis & Co's portfolio in Q3 2018, its #584 holding.
  • Thompson Davis & Co first reported a position in Global Blood Therapeutics, Inc. in Q4 2017 and has held it in 4 quarters since.
  • Thompson Davis & Co's Global Blood Therapeutics, Inc. position peaked at $24K in Q2 2018.
  • 184 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q3 2018.

Based on Thompson Davis & Co's 13F filing for Q3 2018, filed 14 Nov 2018.